U.S., March 10 -- ClinicalTrials.gov registry received information related to the study (NCT07457294) titled '1% Clascoterone Cream for the Treatment Acne Vulgaris' on Feb. 26.
Brief Summary: This is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of 1% Clascoterone Cream in the treatment of acne vulgaris.
Target population: Participants aged >=12 years with moderate to severe acne vulgaris who meet the inclusion criteria and none of the exclusion criteria.
Treatment: The investigational group will receive 1% Clascoterone Cream, and the control group will receive placebo. Approximately 1 g of the cream will be applied evenly to the entire face twice daily ...